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Autonomic and somatic denervation is well established in Parkinson's disease (PD).
Objectives: (1) To determine whether corneal confocal microscopy (CCM) can non-invasively demon-
strate small nerve ﬁber damage in PD. (2) To identify relationships between corneal nerve parameters,
intraepidermal nerve ﬁber density (IENFD) and clinical features of PD.
Methods: Twenty-six PD patients and 26 controls underwent CCM of both eyes. 24/26 PD patients and
10/26 controls underwent skin biopsies from the dorsa of both feet. PD patients underwent assessment
of parasympathetic function [deep breathing heart rate variability (DB-HRV)], autonomic symptoms
[scale for outcomes in Parkinson's disease e autonomic symptoms (SCOPA-AUT)], motor symptoms
[UPDRS-III “ON”] and cumulative Levodopa dose.
Results: PD patients had signiﬁcantly reduced corneal nerve ﬁber density (CNFD) with increased corneal
nerve branch density (CNBD) and corneal nerve ﬁber length (CNFL) compared to controls. CNBD and
CNFL but not CNFD correlated inversely with UPDRS-III and SCOPA-AUT. All CCM parameters correlated
strongly with DB-HRV. There was no correlation between CCM parameters and disease duration, cu-
mulative Levodopa dose or pain. IENFD was signiﬁcantly reduced in PD compared to controls and
correlated with CNFD and UPDRS-III. However, unlike CCM measures, IENFD correlated with disease
duration and cumulative Levodopa dose but not with autonomic dysfunction.
Conclusion: CCM identiﬁes corneal nerve ﬁber pathology, which correlates with autonomic symptoms,
parasympathetic deﬁcits and motor scores in patients with PD. IENFD is also reduced and correlates with
CNFD and motor symptoms but not parasympathetic deﬁcits, indicating it detects different aspects of
peripheral nerve pathology in PD.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)., Greater Manchester Neuro-
Salford, United Kingdom.
chester.ac.uk (L. Kass-Iliyya),
), david.gosal@srft.nhs.uk
k (C. Kobylecki), andrew.
2002@qatar-med.cornell.edu
Ponirakis), mitra.tavakoli@
nchester.ac.uk (M. Ferdousi),
a.jeziorska@manchester.ac.uk
. Malik), monty.silverdale@
r Ltd. This is an open access article1. Introduction
Parkinson's disease (PD) is a neurodegenerative disease recog-
nized clinically by its motor symptoms of rest tremor, bradykinesia,
rigidity and postural instability. The motor syndrome results from
degeneration of dopaminergic neurons in the substantia nigra.
Abnormal aggregates of alpha-synuclein in neuronal cells form the
histopathological hallmark of PD.
A substantial body of evidence demonstrating peripheral nerve
pathology has challenged the traditional view of PD as a disorder ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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posits have been demonstrated in the autonomic nerves of the
colon, cardiac plexus and more recently cutaneous C ﬁbers [1e5].
Several studies have shown clinical and histopathological evi-
dence of small and large ﬁber peripheral neuropathy in PD [6e10].
To date there is no consensus on the underlying pathophysiology of
peripheral neuropathy in PD. Cumulative Levodopa exposure has
been proposed as a potential cause for large ﬁber neuropathy via
homocysteine accumulation and reduced levels of folate as well as
vitamin B12 [6,9,10]. However several studies have found no rela-
tion between peripheral denervation and Levodopa exposure sug-
gesting that peripheral nerve involvement may be an intrinsic
feature of the disease, especially in relation to small ﬁber neurop-
athy [1,7,11]. Furthermore, the identiﬁcation of alpha-synuclein in
cutaneous nerves has led to the consideration of skin tissue as a
potential biomarker in PD [2,5].
The cornea receives its innervation from the ophthalmic branch
of the trigeminal nerve. Corneal nerves have an important neuro-
trophic role in maintaining corneal integrity. Small unmyelinated
nerve ﬁbers enter the cornea from the periphery and course
through the corneal stroma before they penetrate the sub-
epithelial Bowman's membrane, giving rise to the sub-basal
nerve plexus [12]. This nerve plexus is of particular relevance for
deﬁning neuropathic changes since it supplies the overlying
corneal epithelium. We have developed corneal confocal micro-
scopy (CCM) as a rapid, non-invasive technique for in vivo visuali-
zation of corneal nerves and shown it to be a valid surrogate
measure of diabetic somatic and autonomic neuropathy [13,14].
CCM can also detect early neuropathy in patients with recently
diagnosed type 2 diabetes and subjects with impaired glucose
tolerance [15,16]. Furthermore, CCM has a high sensitivity in
detecting early nerve regeneration following simultaneous
pancreas and kidney transplantation in diabetic neuropathy [17].
We have further extended the role of CCM to detect small ﬁber
neuropathy in Fabry's disease, idiopathic small ﬁber neuropathy
and CharcoteMarieeTooth 1A [18e20].
One study that included 4 patients with PD reported no signif-
icant reduction in corneal nerve density compared to controls [21].
However, assessment of corneal nerve morphology was not the
primary aim of the study and the small number of PD participants
precludes meaningful conclusions regarding the utility of CCM in
PD.
Given the strong evidence for small ﬁber neuropathy in PD, we
hypothesized that CCM would allow rapid, non-invasive detection
of corneal nerve pathology and that this would be related to
intraepidermal nerve ﬁber density and clinical symptoms in PD, in
particular those related to pain and autonomic dysfunction.
2. Methods
2.1. Ethical approval
NRES Committee/North West (Ref. No 12/NW/0086) approved
the study.
2.2. Subjects
Thirty-three patients (22 males, 11 females) fulﬁlling the UK
Brain Bank criteria for the diagnosis of Parkinson's disease were
recruited from neurology clinics. Patients with a known history of
cancer, chemotherapy, diabetes, alcoholism, vitamin deﬁciencies,
celiac disease and autoimmune conditions were excluded. All pa-
tients underwent an oral glucose tolerance test and fasting blood
screening to include: vitamin B12, folate, methylmalonate, and
homocysteine to exclude other causes of neuropathy. Six patients (5males, 1 female) were excluded due to impaired glucose tolerance,
leaving 27 patients who fulﬁlled the inclusion criteria. CCMwas not
undertaken in 1 patient due to previous refractive eye surgery.
Twenty-six age-matched healthy volunteers served as controls. All
participants gave their written informed consent.
2.3. Disease duration, severity and levodopa exposure
PD durationwas calculated from reported symptoms onset until
the date of assessment. UPDRS-III was used to assess motor
severity. Patients were examined in the “ON” state in an outpatient
setting. All patients except one were on Levodopa therapy. Cumu-
lative Levodopa dose was calculated from the date of ﬁrst pre-
scription until the date of assessment.
2.4. Non-motor symptoms
Non-motor symptoms were quantiﬁed using the non-motor
symptoms scale NMSS [22]. Pain was quantiﬁed separately using
the recently devised King's PD pain scale [23] as well as the short
form McGill Pain Questionnaire (SFMPQ).
2.5. Autonomic symptoms and function
Autonomic symptoms were assessed using the scale for out-
comes in Parkinson's disease e autonomic symptoms (SCOPA-AUT)
[24]. Deep breathing heart rate variability (DB-HRV) provided an
estimation of cardiac parasympathetic dysfunction and was
assessed with an ANX 3.0 autonomic nervous system devise
(ANSAR Medical Technologies Inc., Philadelphia, PA). Cardiovascu-
lar sympathetic functionwas assessed bymeasuring blood pressure
and heart rates in the supine position and after standing up for
5 min.
2.6. Evaluation of neuropathy
Nerve conduction studies were performed on all PD patients.
Patients with evidence of a large ﬁber neuropathy underwent
assessment of immunoglobulins and protein electrophoresis to rule
out the presence of a paraproteinemic neuropathy. The neuropathy
disability score (NDS) was obtained in all participants. NDS is a
bedside measure to stratify diabetic neuropathy [25]. A clinician
assesses vibration perception using a tuning fork, temperature
perception using a cold and warm metal rods, pinprick perception
using Neurotips™ and ankle reﬂexes using a tendon hammer
producing a score from 0 to 10. Quantitative Sensory Testing was
assessed using the MEDOC TSA II (Medoc Ltd., Ramat-Yishai 20095,
Israel) device on the dorsum of the left foot. Quantitative sensory
testing included heat sensation threshold, heat-induced pain
threshold, cold threshold and cold-induced pain threshold. Vibra-
tion perception threshold was measured using a Neurothesiometer
(Horwell, Scientiﬁc Laboratory Supplies, Nottingham, UK) on the
hallux of both feet.
2.7. Skin biopsies
Two 3-mm punch skin biopsies were taken from the dorsa of
both feet. The biopsies were immediately ﬁxed in 4% para-
formaldehyde, cryoprotected in graded solutions of sucrose, frozen
and cut on a cryomicrotome (HM450, Microm International, Ger-
many). Six 50 mm sections per biopsy were immuno-stained using
anti-human PGP 9.5 antibody and nerve ﬁbers were demonstrated
using SG chromogen (Vector Laboratories, Peterborough, U.K.). A
pathologist blinded to participants' details performed tissue anal-
ysis. Intraepidermal nerve ﬁber density (IENFD), i.e., the number of
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cording to established criteria and expressed as number per milli-
metre of epidermal length [26]. The mean between right and left
IENFD was calculated for each patient and used for analysis.
2.8. Corneal confocal microscopy
Corneal microscopy was performed on both eyes using a Hei-
delberg Retina Tomograph III with a Rostock Cornea Module (HRT
III RCM; Heidelberg Engineering GmbH, Heidelberg, Germany), as
previously described [17]. Four to six high-resolution (1e2 mm)
images of the sub-basal plexus of each eye were obtained for all
participants. A trained investigator who was blinded to partici-
pants' details analysed corneal images separately. Corneal Nerve
Fiber Density (CNFD): The number of main nerves per square mil-
limetre, Corneal Nerve Branch Density (CNBD): The number of
branches emanating from each main nerve per square millimetre
and Corneal Nerve Fiber Length (CNFL): The length of all nerve ﬁ-
bers and branches (mm per squaremillimetre) were quantiﬁed and
the mean derived from the right and left eye for each parameter.
Quantiﬁcation was undertaken using semi-automated, purpose-
written, proprietary software (CCMetrics; M.A. Dabbah, Imaging
Science and Biomedical Engineering, Manchester, UK). To estimate
the error in measuring CNFD, CNBD and CNFL, we acquired images
and determined each of these parameters in 15 subjects on two
occasions separated by at least 48 h. The coefﬁcient of variation of
these parameters was 12% for CNFD, 24% for CNBD and 9% for CNFL.
2.9. Statistical analysis
IBM SPSS version 22 was used to compute the results. All pa-
rameters were normally distributed except for cumulative Levo-
dopa dose, vibration and cold perception thresholds as well as heat
and cold pain thresholds. Independent samples t-test or Man-
neWhitney U test were used to compare means as appropriate.
Cohen dwas calculated to measure effect size. Two-tailed Pearson's
correlation or Spearman's correlations were used as appropriate to
determine relationships between continuous variables. CategoricalTable 1
Demographics, clinical characteristics and quantitative measures of neuropathy in patien
PD patients (n ¼ 27)
Gender 10 females, 17 males
Age (years) 63.0 ± 1.5 (49e77)
Disease duration (years) 6.6 ± 0.9 (0.7e21)
UPDRS-III 26.6 ± 2.3 (10e53)
Hoehn and Yahr Stage. I ¼ 10, II ¼ 13, III ¼ 4
Cumulative Levodopa dose (g) 750.7 ± 165.8 (0e4145.6)
SCOPA-AUT 15.22 ± 1.3 (4e30)
NMSS 59.9 ± 5.2 (2e117)
King's PD pain scale 21.0 ± 3.0 (0e53)
SFMPQ 21.0 ± 2.5 (0e51)
NDS 3 ± 0.5 (0e9)
DB-HRV (beats/min) 15.6 ± 1.3 (6e28)
Supine systolic BP (mm Hg) 128.5 ± 3.7 (106e188)
Supine diastolic BP (mm Hg) 75.3 ± 1.7 (60e90)
Supine heart rate (beats/min) 71.5 ± 2.6 (53e97)
Standing systolic BP (mm Hg) 129.7 ± 4.4 (107e204)
Standing diastolic BP (mm Hg) 77.4 ± 2.6 (48e98)
Standing heart rate (beats/min) 76 ± 2.8 (59e101)
Vibration perception threshold 16.4 ± 1.9 (4.8e41)
Cold perception thresholdC 20.8 ± 2 (0e29.8)
Heat perception thresholdC 42 ± 0.8 (36.1e48.7)
Cold pain thresholdC 4 ± 1.5 (0e23.8)
Heat pain thresholdC 47.7 ± 0.6 (39e50)
Unless otherwise stated data are shown as mean ± SEM (range). UPDRS-III: Uniﬁed Parkin
Autonomic Symptoms, NMSS: Non-Motor Symptoms Scale, SFMPQ: Short FormMcGill Pain
Variability. BP:BloodPressure. Student t testwas appliedexcept for vibrationperception, coldata were compared with Chi square test. P value of <0.05 is
considered statistically signiﬁcant.
3. Results
3.1. Study population
A total of 27 PD patients and 26 controls were enrolled in the
study. There was no signiﬁcant difference in demographics be-
tween PD patients and control subjects (Table 1).
3.2. Corneal and intraepidermal nerve ﬁbers
Twenty-six PD patients and 26 controls underwent CCM and 24
PD patients and 10 controls underwent skin biopsies. Both CNFD
and IENFD were signiﬁcantly lower in PD patients compared to
controls (CNFD mean difference: 5.6 no./mm2, 95% CI [9.2, 2],
P ¼ 0.003; IENFD mean difference: 5.9 no./mm, 95% CI
[7.9, 3.9], P < 0.001). However, CNBD was signiﬁcantly higher in
PD patients compared to controls (CNBDmean difference: 86.6 no./
mm2, 95% CI [55.9, 117.2]), P < 0.001). CNFL was also signiﬁcantly
higher in PD patients (CNFL mean difference: 3.2 mm./mm2, 95% CI
[0.3, 6.1], P ¼ 0.031) (Figs. 1 and 2).
Both IENFD and CCM parameters displayed asymmetry between
sides in PD patients. However, when CCM measures and IENFD
were separated according to the clinically more affected side
(deﬁned by UPDRS-III scores) and the clinically less affected side
there was no signiﬁcant difference in CCM measures or IENFD.
3.3. Clinical, neurophysiological, quantitative sensory and
autonomic measures of neuropathy
NDS, DB-HRV and sensory thresholds all showed impairment in
PD compared to controls (Table 1). Overall, there was no signiﬁcant
postural drop in blood pressure in PD (deﬁned as mean systolic
drop of >20 mm Hg and/or diastolic drop of >10 mm Hg) (Table 1).
Three out of 27 PD patients (11.1%) had large ﬁber axonal neurop-
athy on nerve conduction studies and 2 of these patients had raisedts with Parkinson's disease (PD) and controls.
Controls (n ¼ 26) P Value
11 females, 15 males 0.695
60.1 ± 1.3 (51e73) 0.164
e e
e e
e e
e e
e e
e e
e e
e e
0.8 ± 1.1 (0e4) 0.001
20.9 ± 2.2 (7e40) 0.023
137.0 ± 3.3 (114e180) 0.089
76.4 ± 2.1 (56e97) 0.678
66.0 ± 2.1 (49e89) 0.104
134.9 ± 4.0 (101e189) 0.384
78.7 ± 1.9 (57e100) 0.680
70.8 ± 1.8 (54e90) 0.130
9.1 ± 1.3 (0.7e24.5) 0.001
27.9 ± 0.4 (22.8e31) 0.002
37.7 ± 0.4 (33.6e41.4) <0.001
12.7 ± 1.7 (0e23.9) 0.001
45.5 ± 0.6 (38e50) 0.004
son's Disease Rating Scale, SCOPA-AUT: Scale for Outcomes in Parkinson's Disease e
Questionnaire, NDS: Neuropathy Disability Scale, DB-HRV: Deep Breathing Heart Rate
dperception, headpainand coldpain thresholdswhereMannWhitneyU testwasused.
Fig. 1. Representative examples of 50 mm sections from skin biopsies immunostained
for PGP9.5. Healthy control (A) shows numerous long branching intraepidermal nerve
ﬁbers (red arrows) reaching upper layers of epidermis and well developed sub-
epidermal nerve plexus (green arrows). Biopsy from a patient with Parkinson's dis-
ease (B) showing scant, faintly staining intraepidermal nerve ﬁbers (red arrows), some
branches with axonal swellings (red star) and a biopsy from another patient with
Parkinson's disease (C) showing an area of epidermis with only one short intra-
epidermal nerve ﬁber and signs of degeneration in the sub-epidermal nerve plexus
(red stars). Note short nerve ﬁbers, barely crossing epidermal basement membrane (B,
C, blue arrows). AeC at the same magniﬁcation, scale bar ¼ 100 mm. Corneal confocal
image of a healthy control (D) compared to a patient with Parkinson's disease (E)
showing a reduction in overall corneal nerve ﬁber density and increased corneal nerve
branch density. Quantiﬁcation of corneal nerve ﬁber density, branch density and ﬁber
length is calculated using a semi-automated process. Main ﬁbers are highlighted in
red, branches are highlighted in blue and branch origins are represented by the green
dots (F&G). (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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4 PD patients with normal nerve conduction studies. Homocysteine
was raised in 5 (18.5%) patients all of whom had normal neuro-
physiology. All patients had normal vitamin B12 and folate levels.
Protein electrophoresis was normal in patients with large ﬁber
neuropathy.
3.4. Relation between corneal nerve parameters, intraepidermal
nerve ﬁbers and clinical features
CNFD correlated positively with IENFD in PD patients (Pearson's
r¼ 0.464, P¼ 0.026). Correlations between CCM parameters, IENFD
and clinical data are summarized in Table 2. CNBD and CNFL but not
CNFD correlated inversely with UPDRS-III. There was no correlation
between any of the corneal nerves parameters and disease dura-
tion, cumulative Levodopa dose, non-motor symptoms, pain scales
or sensory thresholds. However, there was an inverse correlation
between heat-induced pain threshold and SFMPQ (Spearman's
rho 0.450, P ¼ 0.036). A signiﬁcant positive correlation was found
between DB-HRV and all corneal nerve parameters, but not IENFD
(Table 2). However, IENFD correlated with disease duration, disease
severity and cumulative Levodopa dose. Both CNFD and IENFD
correlated with NDS. CNFD, IENFD and NDS were independent of
vitamin B12, folate, methylmalonate and homocysteine levels.
4. Discussion
This is the ﬁrst study to systematically characterize corneal
nerve changes in PD using the non-invasive technique of corneal
confocal microscopy. Compared to controls, PD patients demon-
strated a reduction in CNFD, a marked increase in CNBD and an
increase in CNFL. This pattern of corneal nerve pathology is notably
different from diabetes, Fabry's disease, chronic inﬂammatory
demyelinating polyneuropathy and CharcoteMarie Tooth 1A,
where a reduction of all three corneal nerve parameters has been
documented [13,18,20,27]. Thus the reduced CNFDwith a markedly
increased CNBD appears to be unique in PD. Pathologically this
represents small ﬁber neuropathy, characterized by the reduced
CNFD. However, the increased CNBD is likely to reﬂect attempted
nerve regeneration. Increased branching of nerve ﬁbers in PD has
been previously reported on skin biopsies signifying attempts at
nerve regeneration [8]. In our PD patients CNBD correlated
inversely with motor severity suggesting that nerve regeneration
occurs in the early stages of the disease and declines as the disease
becomes more advanced. Indeed, increased corneal nerve branch
density was the ﬁrst measure to increase after simultaneous
pancreas and kidney transplantation or continuous subcutaneous
insulin infusion in type 1 diabetes [17,28].
We conﬁrm the results of a number of studies, which have
shown a reduction of distal IENFD in PD patients [5,7,8]. However,
we are the ﬁrst to report a reduction of CNFD, which correlates with
IENFD indicating widespread involvement of small nerve ﬁbers in
PD. This is further supported by the signiﬁcant impairment of
modalities relating to both parasympathetic and sensory functions
(DB-HRV, thermal perception and pain thresholds). We did not
document signiﬁcant postural drop in blood pressure or heart rate
(sympathetic cardiovascular function) in our PD population. Given
that postural hypotension is a manifestation of severe sympathetic
dysfunction this may reﬂect the disease stage of most of our PD
cohort with relatively few patients in very advanced stages
(Table 1).
The change in corneal nerve parameters was independent of
age, cumulative Levodopa dose, methylmalonate, homocysteine,
B12 and folate levels, suggesting that damage to corneal nerves is a
result of an intrinsic disease process rather than external factors.
Fig. 2. Mean ± SEM of corneal nerve ﬁber density (CNFD) (A), intraepidermal nerve ﬁber density (IENFD) (B), corneal nerve ﬁber branch density (CNBD) (C) and ﬁber length (CNFL)
(D) in Parkinson's disease (PD) compared to controls with signiﬁcance level and effect size.
Table 2
Correlations between corneal nerve measures, intraepidermal nerve ﬁber density
and various clinical and demographic data of PD patients.
CNFD CNBD CNFL IENFD
Age 0.362 0.002 0.104 0.097
Disease duration 0.284 0.181 0.210 ¡0.416*
Cumulative L-dopa dose 0.301 0.243 0.170 ¡0.476*
UPDRS-III 0.337 ¡0.445* ¡0.416* ¡0.441*
SCOPA-AUT 0.373 ¡0.439* ¡0.405* 0.267
DB-HRV 0.537** 0.681*** 0.708*** 0.174
NMSS 0.042 0.204 0.047 0.353
King's PD pain scale 0.360 0.232 0.243 0.281
SFMPQ 0.053 0.249 0.117 0.071
NDS ¡0.522** 0.328 0.360 ¡0.451*
Vibration threshold 0.133 0.278 0.293 0.354
Cold threshold 0.090 0.242 0.144 0.227
Heat threshold 0.385 0.240 0.282 0.399
Cold pain threshold 0.025 0.303 0.265 0.369
Heat pain threshold 0.336 0.169 0.247 0.094
*P  0.05, **P  0.01, ***P  0.001. Pearson's correlation was applied in all measures
except for Levodopa dose, vibration threshold, cold and heat pain thresholds where
the non-parametric Spearman's correlation was applied. CNFD: Corneal Nerve Fiber
Density, CNBD: Corneal Nerve Branch Density, CNFL: Corneal Nerve Fiber Length,
IENFD: Intraepidermal Nerve Fiber Density, UPDRS-III: Uniﬁed Parkinson's Disease
Rating Scale, SCOPA-AUT: Scale for Outcomes in Parkinson's Disease e Autonomic
Symptoms, DB-HRV: Deep Breathing Heart Rate Variability, NMSS: Non-Motor
Symptoms Scale, SFMPQ: Short Form McGill Pain Questionnaire, NDS: Neuropathy
Disability Scale.
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symmetrical [29] we found asymmetry in corneal nerve parame-
ters between sides in PD patients suggesting that corneal neurop-
athy in diabetes is due to a global metabolic process, whereas in PD
may be due to a more localized degenerative process consistent
with PD pathology.
Corneal nerve changes strongly correlated with autonomic
symptoms (SCOPA-AUT) and parasympathetic dysfunction (DB-
HRV), but did not correlate with disease duration or cumulative
Levodopa dose. However, IENFD correlated with disease duration,
and cumulative Levodopa dose but not with autonomic symptoms
or parasympathetic deﬁcits (Table 2). These ﬁndings suggest thatCCM and skin biopsies may be reﬂecting different aspects of
neuronal pathology in PD and indeed corneal nerves changes rather
than IENFD are more closely associated with autonomic pathology.
In support of this we have recently shown that CCM has a very high
sensitivity and speciﬁcity for the diagnosis of diabetic autonomic
neuropathy and correlates with autonomic symptoms and deﬁcits
[14]. The moderate correlation between IENFD and CNFD empha-
sizes that skin biopsy and CCM are visualizing different aspect of
small ﬁber pathology. Indeed in a recent study of 134 patients with
early diabetic neuropathy the association between IENFD and CCM
pathology was even lower [16]. It would be interesting to investi-
gate whether corneal denervation is present during the pre-motor
phase when autonomic symptoms are commonly reported which
can potentially add to the sensitivity and speciﬁcity of pre-motor
features such as anosmia and REM sleep behaviour disorder in
diagnosing pre-motor PD.
Previous studies of skin biopsies in PD have revealed preferen-
tial deposition of phosphorylated alpha-synuclein in autonomic
cutaneous nerves, with a higher yield for alpha-synuclein from
proximal as opposed to distal sites [2,5]. IENFD reduction, on the
other hand, follows a length-dependent pattern [7]. This has led to
the suggestion that alpha-synuclein deposition and a length-
dependent reduction in IENFD are different pathological pro-
cesses [7]. Distal skin denervation in our PD patients was more
pronounced than corneal denervation (Fig. 2). Taken together one
may conclude that the difference of alpha-synuclein deposition
between proximal and distal sites may reﬂect neuronal availability
with distal axons being more vulnerable to degeneration compared
to proximal sites.
Similar to previous reports we found otherwise unexplained
clinical and neurophysiological evidence of large ﬁber neuropathy
in a proportion of our PD patients but we could not establish a link
between levodopa exposure or vitamin deﬁciencies and large ﬁber
neuropathy. The question of Levodopa induced neuropathy in PD
remains a subject of debate. While there have been reports linking
large ﬁber neuropathy with prolonged exposure to Levodopa [6,9],
evidence for such a link with small ﬁber neuropathy is lacking
[1,2,7,11]. Althoughwe have found a correlation between IENFD and
L. Kass-Iliyya et al. / Parkinsonism and Related Disorders 21 (2015) 1454e1460 1459cumulative Levodopa dose, establishing causality is difﬁcult as
reduced IENFD also correlated with disease duration and severity.
Correcting for these factors using multiple regression analysis may
address this question, but our study was not powered for this.
However, given the lack of relationship between changes in IENFD
and methylmalonate, homocysteine or B12 as well as the asym-
metry between skin biopsies, our results suggest that cutaneous
denervation may be due to an intrinsic disease process rather than
an extrinsic toxicity due to Levodopa.
Pain is very common in PD, affecting up to 70% of PD patients
[30]. We found no correlation between self-reported pain scores
and small ﬁber nerve density suggesting that small ﬁber pathology
may make a lower contribution to pain in PD and that more central
mechanisms are involved. This is further supported by the inverse
correlation between heat-induced pain threshold and SFMPQ
indicating a reduced pain threshold in painful PD phenotypes. Thus
pain in PD ismore likely to be due to an impaired central processing
of nociceptive inputs rather than damaged peripheral nerves.
Both CNBD and CNFL as well as IENFD correlated negatively with
UPDRS-III. These ﬁndings strengthen the argument that skin biopsy
and CCM may be useful biomarkers in PD. Of course our study was
not designed to assess the utility of these measures as biomarkers
and is limited by the cross sectional design and the assessment of
UPDRS-III in the “ON” state, potentially affecting the ability to
interpret the motor severity data. Furthermore, skin tissue co-
immunostaining with vasoactive intestinal peptide (VIP) or tyro-
sine hydroxylase would have been required to detect sympathetic
adrenergic ﬁbers and differentiate autonomic from sensory nerve
involvement. These limitations, however, did not affect our primary
objective, which was to assess corneal nerve pathology in PD
compared to healthy controls and this was demonstrated with
signiﬁcant effect size.
Corneal confocal microscopy, a rapid non-invasive imaging
technique, allows in vivo visualization and quantiﬁcation of corneal
nerves. This enables longitudinal assessment of small nerve ﬁber
pathology, which is not readily achieved using skin biopsies in PD.
Further longitudinal studies using UPDRS-III “OFF” scores are
needed to establish its relationship to motor deﬁcits. Whether CCM
can indeed fulﬁl the criteria of a non-invasive biomarker to detect
sub-clinical disease, predict progression and the effect of treatment
in PD, remains to be answered.
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